Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 1748-1753, April 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zuckerman, J. E.
Right arrow Articles by Sikic, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuckerman, J. E.
Right arrow Articles by Sikic, B. I.

In Vitro Selection and Characterization of a Bleomycin-resistant Subline of B16 Melanoma1

Joan E. Zuckerman2, Thomas A. Raffin, J. Martin Brown, Robert A. Newman3, B. Bill Etiz and Branimir I. Sikic4

Stanford University School of Medicine, Stanford, California 94305

A subline of B16 melanoma cells which is 10-fold resistant to bleomycin (BLM) was developed by exposure of the parental cell line to sequential increases in BLM concentration. This resistance to BLM is stable for over 30 passages in drug-free medium. Neither double minute chromosomes nor homogeneously staining regions were evident in karyotypes of the resistant cells. The subline, B16/BLM-R1, was slightly radioresistant, with a D0 ratio of 1.4 compared to the parental cells. No cross-resistance was observed to a number of cytotoxic drugs, including doxorubicin, melphalan, cisplatin, carmustine, dactinomycin, mitomycin C, and vinblastine. However, slight cross-resistance (2-fold) was noted with etoposide. Marked resistance to BLM also was demonstrated in vivo in mice bearing B16/BLM-R1 implanted s.c. Possible mechanisms of BLM resistance in these cells were explored through examination of the degree of drug inactivation by BLM hydrolase and measurement of single- and double-strand DNA scission, as well as repair of single strand breaks by the alkaline elution technique. The specific activity of BLM hydrolase was 70% higher in the resistant subline, commensurate with a 50% increase in protein content in these cells. Because this is insufficient to account for the 10-fold resistance, BLM hydrolase activity does not appear to be a major determinant of resistance in B16/BLM-R1. The overall number of single and double strand breaks in DNA produced by bleomycin treatment did not differ in the sensitive and resistant cells. The cross-resistance with ionizing radiation and etoposide suggests an enhanced capability of B16/BLM-R1 cells to withstand or repair single strand breaks in DNA. However, this was not evident by measuring repair of single strand scission by alkaline elution.

1 Supported by NIH Grants CA-27478, CA-29901, CA-15201, RCDA-CA-0777 and by the American Lung Association.

2 Recipient of an Individual National Research Service Award (HL-6618), from the USPHS. Present address: Department of Chemotherapy Research, M. D. Anderson Hospital and Tumor Institute, Houston, TX 77030.

3 Present address: Department of Chemotherapy Research, M. D. Anderson Hospital and Tumor Institute, Houston, TX 77030.

4 Recipient of a Faculty Development Award in Clinical Pharmacology from the Pharmaceutical Manufacturers Association Foundation. To whom requests for reprints should be addressed at Room M-211, Oncology Division, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305.

Received 7/16/85. Revised 12/30/85. Accepted 1/ 2/86.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
E. P. v. Strandmann, S. Senkel, G. Ryffel, and U. R. Hengge
Dimerization Co-Factor of Hepatocyte Nuclear Factor 1/Pterin-4{{alpha}}-Carbinolamine Dehydratase Is Necessary for Pigmentation in Xenopus and Overexpressed in Primary Human Melanoma Lesions
Am. J. Pathol., June 1, 2001; 158(6): 2021 - 2029.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.